Published in PLoS One on September 14, 2015
Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. EMBO Rep (2016) 0.86
Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy. Toxins (Basel) (2016) 0.81
Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors. Nat Rev Microbiol (2017) 0.78
Correction: Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs. PLoS One (2015) 0.75
Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet (2006) 15.99
Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis (2006) 8.17
Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science (2007) 7.06
Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis (2008) 4.16
Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog (2010) 3.11
Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun (1995) 3.08
Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A (2010) 3.05
The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol (2008) 2.78
Phage conversion of Panton-Valentine leukocidin in Staphylococcus aureus: molecular analysis of a PVL-converting phage, phiSLT. Gene (2001) 2.67
Global changes in Staphylococcus aureus gene expression in human blood. PLoS One (2011) 2.61
Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol (1995) 2.25
Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol (2007) 2.19
The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect (2008) 2.14
A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J Infect Dis (2009) 2.12
Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem (2004) 2.07
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature (2012) 1.85
Characterization of a novel structural member, LukE-LukD, of the bi-component staphylococcal leucotoxins family. FEBS Lett (1998) 1.81
Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore. Protein Sci (2002) 1.73
Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol (2010) 1.71
The staphylococcal toxin Panton-Valentine Leukocidin targets human C5a receptors. Cell Host Microbe (2013) 1.66
Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol Microbiol (2011) 1.64
Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J Hosp Infect (2007) 1.57
Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect Immun (1999) 1.52
Pore formation by a two-component leukocidin from Staphylococcus aureus within the membrane of human polymorphonuclear leukocytes. Biochim Biophys Acta (1993) 1.51
Panton-valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One (2009) 1.48
Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc Natl Acad Sci U S A (2013) 1.45
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis (2012) 1.40
Flow cytometric determination of Panton-Valentine leucocidin S component binding. Infect Immun (2001) 1.34
The interaction of Staphylococcus aureus bi-component gamma-hemolysins and leucocidins with cells and lipid membranes. Biochim Biophys Acta (1998) 1.31
Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis (2012) 1.30
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One (2012) 1.20
Channel-forming leucotoxins from Staphylococcus aureus cause severe inflammatory reactions in a rabbit eye model. J Med Microbiol (1997) 1.11
The staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun (2014) 1.11
Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol (2012) 1.11
Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. J Infect Dis (2010) 1.10
Models matter: the search for an effective Staphylococcus aureus vaccine. Nat Rev Microbiol (2014) 1.08
Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections. J Clin Microbiol (1989) 1.02
Assembly of Staphylococcus aureus leukocidin into a pore-forming ring-shaped oligomer on human polymorphonuclear leukocytes and rabbit erythrocytes. Biosci Biotechnol Biochem (1999) 1.01
Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis (2012) 0.98
Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One (2012) 0.95
Identification of a crucial residue required for Staphylococcus aureus LukAB cytotoxicity and receptor recognition. Infect Immun (2013) 0.93
Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun (2013) 0.91
Essential binding of LukF of staphylococcal gamma-hemolysin followed by the binding of H gamma II for the hemolysis of human erythrocytes. Biosci Biotechnol Biochem (1995) 0.90
Staphylococcus aureus survival in human blood. Virulence (2011) 0.90
Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model. PLoS One (2013) 0.88
Engineered covalent leucotoxin heterodimers form functional pores: insights into S-F interactions. Biochem J (2006) 0.87
Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy. Toxins (Basel) (2014) 0.85
Prevalence of genes encoding for staphylococcal leukocidal toxins among clinical isolates of Staphylococcus aureus from implant orthopedic infections. Int J Artif Organs (2007) 0.79